ERBB2 and cancer: Multivariate analyses showed that there was a different distribution of Ob-R overexpression according to cancer subtype; for example, patients with HER2 or TNBC breast cancer had significantly higher Ob-R cell positivity than patients with luminal subtypes (Table 2).